Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance
Abbott reported Q3 2026 sales of $13.013 billion, up 14.5% reported and 7.0% on a comparable basis, with GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.42, up 9.2% year-over-year. Management reaffirmed the midpoint of full-year 2026 adjusted EPS guidance and tightened the range to $5.50-$5.55, and guided Q4 adjusted EPS to $1.62-$1.67 on approximately 6.0% comparable sales growth. Growth was broad-based: Diagnostics rose 46.7% reported (boosted by the Exact Sciences acquisition closed March 23, 2026, comparable +6.4%), Medical Devices grew 6.9% reported, and the board declared the company's 411th consecutive quarterly dividend of $0.63 per share.
Key figures
- Eps
- $0.53 GAAP / $1.42 adjusted (adjusted +9.2% YoY vs $1.30)
- Revenue
- 13013000000
- Guidance
- FY2026 comparable sales growth ~6.0%; FY2026 adjusted diluted EPS $5.50-$5.55 (midpoint reaffirmed, range tightened); Q4 2026 adjusted EPS $1.62-$1.67
- Revenue Yoy
- 14.5%
- Nutrition sales
- 2262000000
- Diagnostics sales
- 3305000000
- Net earnings gaap
- 920000000
- Medical devices sales
- 5826000000
- Net earnings adjusted
- 2477000000
- Operating income gaap
- 1358000000
- Comparable sales growth
- 7.0%
- Established pharma sales
- 1614000000
- Quarterly dividend per share
- 0.63
- Legal settlements specified items
- $670 million (Gill case and NEC claims, ~2,000 infants)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.